Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A systematic review finds Incomplete excision rates for basal cell carcinoma range from 4.7% to 20.4% against recommended guidelines of 5%.

A doctor examines moles on a woman's back

Nonmelanoma skin cancer (NMSC), either basal cell carcinoma (BCC) or squamous cell carcinoma (SCC), is the commonest cancer worldwide. The usual treatment is surgical excision, where a cut is made around the malignancy including an area of normal tissue, removing all of the skin cancer cells and curing the patient.

Guidelines published by the British Association of Dermatologists quote a 5% incomplete excision rate, enabling practitioners to advise patients on possible outcomes and providing a benchmark for audit targets.

However, in a new study published in the British Journal of Dermatology, Abhilash Jain, Associate Professor of Plastic and Hand Surgery at NDORMS, University of Oxford reveals that current guidelines underestimate the rates of incomplete excision.

“We found that the proportion of incomplete excisions is actually 11% for basal cell carcinomas, more than double the current guidelines,” said Jain. “That’s important because as practitioners, globally, we need to be able to give our patients information about possible chances of failure. A one in 20 rate is significantly different to a one in ten.”

Incomplete excisions may require further surgery or increased surveillance, which burdens patients and healthcare systems, increasing the costs and morbidity of skin cancer care.

For the study, a trainee group of young plastic surgeons carried out the most comprehensive review to date of primary clinical studies. They analysed 3477 citations in 100 separate studies with a total of 106,832 BCC and 21,569 SCC excisions included. Importantly, Mohs micrographic surgeries were excluded from the analysis as their near 100% success rate obscures the real figures.

Variations in the incomplete excision rate ranged from 4.7% to 20.4%. Differences were found by operating specialty (dermatologists, plastic surgeons, general practitioners, ophthalmology etc.). 

Abhilash said: “The variance can be explained by many factors including the degree of surgical training within the specialty and the complexity of the surgery. We would argue that a 5% blanket rate is not correct but that excision by specialists may reduce treatment failure. Our recommendation is that guidelines are refined to take account of the type of tumour, and to the specialism of surgeons performing the procedure. This will give us a better idea of what we tell our patients, and also how we audit our outcomes.

A forthcoming audit of current plastic surgery outcomes in the UK will provide the evidence to support amendments to update current guidelines,” he concluded.

Similar stories

The new Botnar strategy is announced

After a year as the Director of the Botnar Institute for Musculoskeletal Sciences, Professor Jonathan Rees announces a new structure and strategy that will further enhance research and treatment of bone, joint and musculoskeletal conditions.

New global health grant to improve outcomes for patients with hip fracture

Hip fracture patients in Low- and Middle-Income Countries (LMIC) in Asia are set to benefit from a new study that aims to bring best practice programmes to improve quality of life for patients and reduce healthcare costs.

NDORMS welcomes great-granddaughter of former Head of Department

Julia Strubell, great-granddaughter of Professor Josep Trueta, visited NDORMS to find out about his time here and to share her own work with staff and students.

Botnar researchers awarded Fellowships

Arani Vivekanantham has been awarded an NIHR Doctoral Fellowship and a Versus Arthritis Clinical Research Fellowship, and Rachel Kuo was awarded an NIHR Doctoral Research Fellowship.

Better diagnosis and treatment of autoimmune diseases moves a step closer

A study published in Nature outlines a way to find the crucial peptides (protein fragments) that drive autoimmunity, as well as the immune cells that respond to them.

New drug offers hope for people with hand osteoarthritis

A new study, published in Science Translational Medicine by researchers at the University of Oxford has identified that Talarozole, a drug that is known to increase retinoic acid, was able to prevent osteoarthritis (OA) in disease models.